4188 Stock Overview
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AmCad BioMed Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.10 |
| 52 Week High | NT$37.40 |
| 52 Week Low | NT$15.75 |
| Beta | 0.90 |
| 1 Month Change | -5.90% |
| 3 Month Change | -16.87% |
| 1 Year Change | 67.28% |
| 3 Year Change | 41.88% |
| 5 Year Change | -1.99% |
| Change since IPO | -56.98% |
Recent News & Updates
Shareholder Returns
| 4188 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 5.7% | 0.3% | -0.6% |
| 1Y | 67.3% | 5.6% | 29.2% |
Return vs Industry: 4188 exceeded the TW Medical Equipment industry which returned 5.6% over the past year.
Return vs Market: 4188 exceeded the TW Market which returned 29.2% over the past year.
Price Volatility
| 4188 volatility | |
|---|---|
| 4188 Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4188's share price has been volatile over the past 3 months.
Volatility Over Time: 4188's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Yi-Li Lee | www.amcad.com.tw |
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases, such as thyroid cancers, fatty liver, liver fibrosis, and obstructive sleep apnea. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients.
AmCad BioMed Corporation Fundamentals Summary
| 4188 fundamental statistics | |
|---|---|
| Market cap | NT$1.44b |
| Earnings (TTM) | -NT$45.31m |
| Revenue (TTM) | NT$65.26m |
22.1x
P/S Ratio-31.9x
P/E RatioIs 4188 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4188 income statement (TTM) | |
|---|---|
| Revenue | NT$65.26m |
| Cost of Revenue | NT$24.23m |
| Gross Profit | NT$41.02m |
| Other Expenses | NT$86.34m |
| Earnings | -NT$45.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 62.87% |
| Net Profit Margin | -69.44% |
| Debt/Equity Ratio | 0% |
How did 4188 perform over the long term?
See historical performance and comparison